146 related articles for article (PubMed ID: 36572866)
1. Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor.
Kanada R; Kagoshima Y; Suzuki T; Nakamura A; Funami H; Watanabe J; Asano M; Takahashi M; Ubukata O; Suzuki K; Aikawa T; Sato K; Goto M; Setsu G; Ito K; Kihara K; Kuroha M; Kohno T; Ogiwara H; Isoyama T; Tominaga Y; Higuchi S; Naito H
J Med Chem; 2023 Jan; 66(1):695-715. PubMed ID: 36572866
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP.
Nie S; Wu F; Wu J; Li X; Zhou C; Yao Y; Song Y
Eur J Med Chem; 2022 Jul; 237():114407. PubMed ID: 35512565
[TBL] [Abstract][Full Text] [Related]
3. Is histone acetylation the most important physiological function for CBP and p300?
Bedford DC; Brindle PK
Aging (Albany NY); 2012 Apr; 4(4):247-55. PubMed ID: 22511639
[TBL] [Abstract][Full Text] [Related]
4. Early Drug-Discovery Efforts towards the Identification of EP300/CBP Histone Acetyltransferase (HAT) Inhibitors.
Huhn AJ; Gardberg AS; Poy F; Brucelle F; Vivat V; Cantone N; Patel G; Patel C; Cummings R; Sims R; Levell J; Audia JE; Bommi-Reddy A; Wilson JE
ChemMedChem; 2020 Jun; 15(11):955-960. PubMed ID: 32181984
[TBL] [Abstract][Full Text] [Related]
5. Acetyltransferases CBP/p300 Control Transcriptional Switch of β-Catenin and Stat1 Promoting Osteoblast Differentiation.
Zhang L; Zhu K; Xu J; Chen X; Sheng C; Zhang D; Yang Y; Sun L; Zhao H; Wang X; Tao B; Zhou L; Liu J
J Bone Miner Res; 2023 Dec; 38(12):1885-1899. PubMed ID: 37850815
[TBL] [Abstract][Full Text] [Related]
6. Discovery of EP300/CBP histone acetyltransferase inhibitors through scaffold hopping of 1,4-oxazepane ring.
Kanada R; Kagoshima Y; Asano M; Suzuki T; Murata T; Haruta M; Takahashi M; Ubukata O; Hashimoto K; Obata K; Kihara K; Kuroha M; Banjo T; Togashi N; Sato K; Yamamoto Y; Suzuki K; Isoyama T; Tominaga Y; Higuchi S; Naito H
Bioorg Med Chem Lett; 2022 Jun; 66():128726. PubMed ID: 35413416
[TBL] [Abstract][Full Text] [Related]
7. Spatial memory consolidation is associated with induction of several lysine-acetyltransferase (histone acetyltransferase) expression levels and H2B/H4 acetylation-dependent transcriptional events in the rat hippocampus.
Bousiges O; Vasconcelos AP; Neidl R; Cosquer B; Herbeaux K; Panteleeva I; Loeffler JP; Cassel JC; Boutillier AL
Neuropsychopharmacology; 2010 Dec; 35(13):2521-37. PubMed ID: 20811339
[TBL] [Abstract][Full Text] [Related]
8. Discovery of berberine analogs as potent and highly selective p300/CBP HAT inhibitors.
Zhong X; Deng H; Long M; Yin H; Zhong Q; Zheng S; Gong T; He L; Wang G; Sun Q
Bioorg Chem; 2023 Sep; 138():106597. PubMed ID: 37245245
[TBL] [Abstract][Full Text] [Related]
9. Assays for Validating Histone Acetyltransferase Inhibitors.
Waddell AR; Liao D
J Vis Exp; 2020 Aug; (162):. PubMed ID: 32831305
[TBL] [Abstract][Full Text] [Related]
10. RNA Binding to CBP Stimulates Histone Acetylation and Transcription.
Bose DA; Donahue G; Reinberg D; Shiekhattar R; Bonasio R; Berger SL
Cell; 2017 Jan; 168(1-2):135-149.e22. PubMed ID: 28086087
[TBL] [Abstract][Full Text] [Related]
11. 4-Pyridone-3-carboxylic acid as a benzoic acid bioisostere: Design, synthesis, and evaluation of EP300/CBP histone acetyltransferase inhibitors.
Kanada R; Suzuki T; Murata T; Miyazaki M; Shimada T; Kuroha M; Minami M; Higuchi S; Tominaga Y; Naito H
Bioorg Med Chem Lett; 2021 Nov; 51():128358. PubMed ID: 34534674
[TBL] [Abstract][Full Text] [Related]
12. Valproic acid exposure decreases Cbp/p300 protein expression and histone acetyltransferase activity in P19 cells.
Lamparter CL; Winn LM
Toxicol Appl Pharmacol; 2016 Sep; 306():69-78. PubMed ID: 27381264
[TBL] [Abstract][Full Text] [Related]
13. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator.
Liu X; Wang L; Zhao K; Thompson PR; Hwang Y; Marmorstein R; Cole PA
Nature; 2008 Feb; 451(7180):846-50. PubMed ID: 18273021
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
15. The ZZ domain of p300 mediates specificity of the adjacent HAT domain for histone H3.
Zhang Y; Xue Y; Shi J; Ahn J; Mi W; Ali M; Wang X; Klein BJ; Wen H; Li W; Shi X; Kutateladze TG
Nat Struct Mol Biol; 2018 Sep; 25(9):841-849. PubMed ID: 30150647
[TBL] [Abstract][Full Text] [Related]
16. Histone acetyltransferase promotes fluoride toxicity in LS8 cells.
Deng H; Fujiwara N; Cui H; Whitford GM; Bartlett JD; Suzuki M
Chemosphere; 2020 May; 247():125825. PubMed ID: 31927229
[TBL] [Abstract][Full Text] [Related]
17. [Histone acetylation and expression of acetylation-related enzymes in children with tetralogy of Fallot].
Xu J; Lin YX; Gu RY; Wang HJ; Ma XJ; Ma D; Huang GY
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Oct; 15(10):817-21. PubMed ID: 24131830
[TBL] [Abstract][Full Text] [Related]
18. Characterization of novel inhibitors of histone acetyltransferases.
Eliseeva ED; Valkov V; Jung M; Jung MO
Mol Cancer Ther; 2007 Sep; 6(9):2391-8. PubMed ID: 17876038
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
[TBL] [Abstract][Full Text] [Related]
20. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
Bowers EM; Yan G; Mukherjee C; Orry A; Wang L; Holbert MA; Crump NT; Hazzalin CA; Liszczak G; Yuan H; Larocca C; Saldanha SA; Abagyan R; Sun Y; Meyers DJ; Marmorstein R; Mahadevan LC; Alani RM; Cole PA
Chem Biol; 2010 May; 17(5):471-82. PubMed ID: 20534345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]